A family office-backed private investment firm founded in the mid-2000s maintains a global presence across North America and Europe. The firm leverages deep operating and investment experience to partner with growth-oriented companies across technology-enabled sectors. The firm deploys flexible capital through venture, growth equity, and private equity strategies, investing across stages from early-stage through later growth rounds. The firm maintains a diversified global portfolio and partners with management teams to drive scalable, long-term value creation.  

The firm invests across technology-enabled consumer and enterprise businesses, as well as healthcare and select life sciences opportunities. Areas of activity include consumer platforms, digital services, biotech, and healthcare services. The firm targets companies with defensible business models, strong competitive positioning, and the ability to scale effectively. The investment approach emphasizes long-term growth, sustainable differentiation, and cross-sector innovation.  

From a company and management team perspective, the firm partners with founders and executives who demonstrate operational excellence, clear strategic vision, and the ability to scale businesses significantly. The firm emphasizes long-term relationships and provides more than capital, offering strategic guidance, operational support, and access to an extensive network. The firm invests through both equity and structured transactions and works collaboratively with leadership teams to support commercialization, product expansion, and organizational growth across global markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a healthcare technology company developing and commercializing AI-powered, laboratory-based diagnostics for early detection and prevention of cancer and chronic diseases. Following a recent financing event tied to public market activity, the firm is allocating a portion of capital toward strategic investments and potential acquisitions. The firm is particularly interested in identifying companies that could serve as future acquisition targets, with a focus on those generating early revenues.  

The firm is actively evaluating opportunities across diagnostics, digital health, and medical devices that address chronic disease detection, longevity, and nutrition-based interventions. Areas of particular interest include solutions that advance “food-as-medicine” approaches and technologies that support prevention and long-term health optimization.  

From a company and management team perspective, the firm does not impose strict requirements but prioritizes companies with demonstrated commercial traction and solutions aligned with its broader platform and strategic roadmap. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a life sciences-focused investment arm of a broader innovation platform, established recently and based in Europe. The firm is actively deploying capital from an early-stage fund and typically makes initial investments in the low single-digit millions. The firm is open to syndicating with co-investors to support portfolio company growth. While the firm has a current geographic emphasis on regional opportunities, it maintains a global investment outlook.  
 
The firm focuses on early-stage biotechnology opportunities emerging from academic and research environments, with a strong emphasis on translational science progressing toward first-in-human studies. The firm prioritizes therapeutic programs supported by robust preclinical data, including modalities such as peptide-based therapeutics. Areas of interest include indications like chronic and nerve-related conditions, among others. The firm seeks programs with a clear and credible path to clinical entry within a defined development timeline, supported by validated targets, strong in vivo data, and early safety work. While therapeutics is the primary focus, the firm actively collaborates with external partners to advance high-potential biological innovations.  
 
From a company and management team perspective, the firm seeks academic founders and early-stage scientific teams developing differentiated therapeutic candidates with strong translational potential. The firm prioritizes opportunities with defensible intellectual property, rigorous preclinical validation, and well-defined development strategies toward IND-enabling studies. The firm works closely with portfolio companies by providing scientific, regulatory, and operational support and engages with teams capable of executing early development milestones. The firm is open to leading or co-leading rounds and partnering with additional investors to support clinical and commercial advancement. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a private investment firm based in Asia, supported by a major scientific research institution and led by professionals with combined experience in R&D, entrepreneurship, and investment across both Asia and the United States. The firm invests in early-stage life sciences and healthcare companies, with typical allocation sizes ranging from approximately $0.5M to $5M. The firm is open to both leading and participating in financing rounds and evaluates opportunities across China and the United States.  

The firm invests broadly across life sciences sectors, including biopharmaceuticals, medical devices, diagnostics, life science R&D services, and healthcare services. The firm has a particular interest in clinical-stage molecular diagnostics and shows comparatively less interest in very early-stage projects, though it remains open to select preclinical opportunities. The firm is disease-agnostic.  

From a company and management team perspective, the firm seeks experienced teams with validated products or technologies. The firm can provide strategic support for regulatory approval and commercialization in China by leveraging a network that includes pharmaceutical partners, CROs and CMOs, academic institutions, and distribution channels. The firm may also seek distribution rights in China and consider board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global investment firm headquartered in Asia invests across the full company lifecycle, from early-stage venture investments through growth equity and buyout transactions. Early-stage investments typically fall in the low single-digit millions. The firm maintains a diversified portfolio, with a dedicated allocation to life sciences and healthcare alongside broader technology investments. The firm invests globally and is actively seeking opportunities outside its home market.  

Within life sciences and healthcare, the firm invests across therapeutics, medical devices, enabling technologies, and AI-driven platforms, particularly those that support or accelerate drug discovery and development. While the firm has historically been active in therapeutics, it has become more selective and is increasingly focused on device innovation, life science tools, enabling technologies, and computational approaches such as AI-based drug discovery. Areas of thematic interest include aging and longevity, immuno-oncology, and advanced therapeutic modalities including cell and gene therapies.  

From a company and management team perspective, the firm prioritizes opportunities with strong scientific or technical foundations, clear differentiation, and the ability to achieve key development milestones. The firm favors teams with deep domain expertise and the capability to execute across both clinical development and commercialization. The firm invests flexibly across stages, typically co-investing alongside established investors and supporting companies with global scaling potential. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A non-profit organization was established to address gaps in drug and device development for small patient populations and underserved markets. The firm focuses on identifying and acquiring stalled or overlooked programs with strong underlying potential, with the goal of advancing them into clinical development, particularly in pediatric and rare disease settings.  

The firm typically adds a small number of new assets each year and is open to engaging with companies globally. While upfront financial commitments are generally modest, the firm structures partnerships to include downstream value sharing, aligning incentives around successful development and commercialization.  

The firm is actively seeking medical device opportunities focused on pediatric applications, particularly solutions for congenital conditions. Areas of interest include technologies that can be tailored or customized to address the unique anatomical and clinical needs of pediatric patients.  

On the therapeutics side, the firm focuses on rare and orphan diseases as well as pediatric oncology. The firm prioritizes assets that are near clinical readiness or already in clinical development, including pre-IND and early clinical-stage programs.  

The firm does not impose strict requirements on company or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.